Vnitr Lek 2008, 54(1):21-24

Monitoring age-dependent effect of anticoagulation treatment in patients with atrial fibrillation

T. Hnátek*, D. Zogala, L. Kameník, I. Kotík, I. Jeřábek, M. Zavoral
Kardiologické oddělení Interní kliniky 1. lékařské fakulty UK a ÚVN Praha, přednosta doc. MUDr. Miroslav Zavoral, Ph.D.

Oral anticoagulation treatment with dicumarol preparations (warfarin sodium) is the standard in patients with atrial fibrillation. The effect of treatment depends on many factors, especially in elderly patients. In the study, we assessed the effect of treatment in patients with atrial fibrillation hospitalized in our cardiology ward from 2004 to 2005, in the form of a telephone survey (who controlled the treatment - general practitioner or internist?, the last 2 INR results, complications). INR 2.0-3.5 is considered an efficient therapeutic range. The proportion of permanently correctly anticoagulated patients is approximately 47 % across the whole age range, the hypothesis of lower efficiency of treatment in elderly patients does not apply (48 % of efficiently anticoagulated patients younger than 75 years vs. 46 % of older patients - however, the study does not include polymorbid patients who could not take warfarin at all!) The fact whether a patient is monitored by a general practitioner or an outpatient specialist does not make any difference (49 % of anticoagulated patients monitored by a general practitioner vs. 52 % of patients monitored by an internist). The percentage of severe complications is relatively low (3.4 %).

Keywords: atrial fibrillation; warfarin; anticoagulation treatment

Received: June 29, 2007; Accepted: September 17, 2007; Published: January 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hnátek T, Zogala D, Kameník L, Kotík I, Jeřábek I, Zavoral M. Monitoring age-dependent effect of anticoagulation treatment in patients with atrial fibrillation. Vnitr Lek. 2008;54(1):21-24.
Download citation

References

  1. Jones M, McEvan P, Morgan C et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients non-valvular atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91: 472-477. Go to original source... Go to PubMed...
  2. Ezekowitz M, Falk R. The Increasing Need for Anticoagulant Therapy to Prevent Stroke in Patients With Atrial Fibrillation. Mayo Clinic Proceedings 2004; 79: 904-913. Go to original source... Go to PubMed...
  3. Reynolds M, Fahrbach K, Hauch O et al. Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation. Chest 2004; 126: 1938-1945. Go to original source... Go to PubMed...
  4. Aschermann M et. al. Kardiologie. Praha: Galén 2004.
  5. Margaret F, Chang Y, Hylek E et al. Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation. Ann Intern Med 2004; 141: 745-752. Go to original source... Go to PubMed...
  6. Gullov A, Koefoed B, Petersen P et al. Bleeding During Warfarin and Aspirin Therapy in Patients With Atrial Fibrillation (The AFASAK 2 Study). Arch Intern Med 1999; 159: 1322-1328. Go to original source... Go to PubMed...
  7. Palareti G, Hirsch J, Legnani C et al. Oral Anticoagulation Treatment in the Elderly. Arch Intern Med 2000; 160: 470-478. Go to original source... Go to PubMed...
  8. Buresly K, Eisenberg MJ, Zhang X et al. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 2005; 165: 784-789. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.